X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (18695) 18695
Newsletter (1068) 1068
Newspaper Article (288) 288
Magazine Article (242) 242
Transcript (164) 164
Book / eBook (18) 18
Dissertation (17) 17
Book Chapter (15) 15
Book Review (5) 5
Publication (5) 5
Web Resource (5) 5
Reference (4) 4
Streaming Video (2) 2
Government Document (1) 1
Pamphlet (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14271) 14271
hypercholesterolemia (9732) 9732
male (9458) 9458
hypercholesterolemia - drug therapy (8422) 8422
female (8016) 8016
middle aged (6955) 6955
cholesterol (5751) 5751
adult (4734) 4734
aged (4618) 4618
risk factors (3675) 3675
cholesterol, ldl - blood (3612) 3612
anticholesteremic agents - therapeutic use (3601) 3601
hypercholesterolemia - blood (3395) 3395
cholesterol - blood (3332) 3332
animals (3270) 3270
atherosclerosis (3127) 3127
statins (3054) 3054
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (2965) 2965
cardiac & cardiovascular systems (2804) 2804
low density lipoproteins (2417) 2417
pharmacology & pharmacy (2252) 2252
hypercholesterolemia - complications (2243) 2243
treatment outcome (2232) 2232
drug therapy (2044) 2044
lipids (2041) 2041
medicine, general & internal (2033) 2033
simvastatin (1981) 1981
familial hypercholesterolemia (1917) 1917
triglycerides - blood (1856) 1856
research (1786) 1786
peripheral vascular disease (1767) 1767
care and treatment (1609) 1609
cardiovascular disease (1601) 1601
lipids - blood (1538) 1538
coronary-heart-disease (1534) 1534
risk (1503) 1503
prevention (1502) 1502
cholesterol, hdl - blood (1499) 1499
atorvastatin (1401) 1401
double-blind method (1391) 1391
health aspects (1352) 1352
pravastatin (1332) 1332
hypolipidemic agents - therapeutic use (1253) 1253
lipoproteins (1245) 1245
disease (1228) 1228
therapy (1220) 1220
cardiovascular diseases (1217) 1217
drug therapy, combination (1179) 1179
analysis (1147) 1147
cardiovascular diseases - prevention & control (1137) 1137
coronary heart disease (1109) 1109
efficacy (1092) 1092
hypertension (1090) 1090
cardiovascular-disease (1058) 1058
cardiovascular (1037) 1037
ezetimibe (1030) 1030
time factors (1025) 1025
adolescent (997) 997
low-density-lipoprotein (985) 985
safety (985) 985
anticholesteremic agents (975) 975
density-lipoprotein cholesterol (974) 974
anticholesteremic agents - pharmacology (968) 968
anticholesteremic agents - administration & dosage (962) 962
rats (959) 959
diet (958) 958
hyperlipidemias - drug therapy (944) 944
dose-response relationship, drug (918) 918
anticholesteremic agents - adverse effects (901) 901
diabetes (897) 897
mice (891) 891
mortality (886) 886
genetic aspects (885) 885
medical research (881) 881
follow-up studies (879) 879
coronary disease - prevention & control (871) 871
hyperlipidemia (870) 870
physiological aspects (862) 862
biochemistry & molecular biology (853) 853
hypercholesterolemia - metabolism (852) 852
myocardial-infarction (843) 843
nutrition & dietetics (843) 843
aged, 80 and over (837) 837
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (836) 836
endocrinology & metabolism (821) 821
antilipemic agents (817) 817
hypercholesterolemia - diet therapy (809) 809
metabolism (802) 802
clinical trials as topic (801) 801
simvastatin - therapeutic use (783) 783
hypercholesterolemia - epidemiology (777) 777
atorvastatin calcium (774) 774
heart-disease (765) 765
prospective studies (757) 757
abridged index medicus (734) 734
blood cholesterol (728) 728
heptanoic acids - therapeutic use (724) 724
medicine & public health (716) 716
medicine, experimental (711) 711
plasma (706) 706
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (8) 8
Online Resources - Online (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Baycrest Hospital - Wellness Library (1) 1
Bridgepoint Health - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - General (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18802) 18802
German (480) 480
French (279) 279
Spanish (241) 241
Japanese (199) 199
Russian (174) 174
Italian (168) 168
Polish (64) 64
Portuguese (62) 62
Dutch (45) 45
Chinese (43) 43
Hungarian (28) 28
Czech (25) 25
Norwegian (20) 20
Danish (19) 19
Swedish (17) 17
Finnish (13) 13
Turkish (11) 11
Romanian (7) 7
Ukrainian (7) 7
Croatian (6) 6
Hebrew (6) 6
Korean (4) 4
Lithuanian (2) 2
Bosnian (1) 1
Estonian (1) 1
Icelandic (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 18, pp. 1713 - 1722
Journal Article
Circulation, ISSN 0009-7322, 04/2007, Volume 115, Issue 14, pp. 1948 - 1967
Despite compliance with lifestyle recommendations, some children and adolescents with high-risk hyperlipidemia will require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia... 
Drugs | Pediatrics | Lipids | Hypercholesterolemia | AHA Scientific Statements | FACTOR INTERVENTION PROJECT | INTIMA-MEDIA THICKNESS | DEPENDENT DIABETES-MELLITUS | lipids | CARDIAC & CARDIOVASCULAR SYSTEMS | LOW-CHOLESTEROL DIET | drugs | LOW-DENSITY-LIPOPROTEIN | RESTORES ENDOTHELIAL FUNCTION | BODY-FAT DISTRIBUTION | hypercholesterolemia | BLOOD-PRESSURE | pediatrics | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | PERIPHERAL VASCULAR DISEASE | LOW-SATURATED-FAT | Dyslipidemias - complications | Humans | Hyperlipoproteinemias - epidemiology | Middle Aged | Child, Preschool | Male | Arteriosclerosis - epidemiology | Phytotherapy | Child | Dyslipidemias - diagnosis | Metabolic Syndrome - epidemiology | Arteriosclerosis - etiology | HIV Protease Inhibitors - adverse effects | Hypolipidemic Agents - adverse effects | Arteriosclerosis - diagnostic imaging | Risk Factors | Combined Modality Therapy | Disease Progression | Arteriosclerosis - prevention & control | Diet, Fat-Restricted | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hyperlipoproteinemia Type II - diet therapy | Adolescent | Age of Onset | HIV Infections - complications | Hypolipidemic Agents - therapeutic use | Arteriosclerosis - pathology | Cholesterol, Dietary | Dyslipidemias - diet therapy | Hyperlipoproteinemias - classification | Age Factors | Hyperlipoproteinemia Type II - diagnosis | Infant | Exercise Therapy | Contraindications | Dietary Fats | Hyperlipoproteinemias - drug therapy | Ultrasonography | Diabetes Complications - epidemiology | Adult | Cholesterol, LDL - blood | Female | Anticholesteremic Agents - classification | Hyperlipoproteinemia Type II - drug therapy | Hyperlipoproteinemia Type II - complications | Dyslipidemias - drug therapy | Clinical Trials as Topic | Anticholesteremic Agents - therapeutic use | Hyperlipoproteinemia Type II - epidemiology | Obesity - epidemiology | Hypolipidemic Agents - administration & dosage | HIV Infections - drug therapy | Hyperlipoproteinemias - genetics | Care and treatment | Demographic aspects | Hyperlipidemia | Research | Drug therapy | Risk factors
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 16, pp. 1489 - 1499
...% when added to background statin therapy. 1 – 3 However, this new treatment needs to be evaluated in larger populations for longer periods of follow-up to establish its safety and efficacy. 4... 
no | CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | DESIGN | THERAPY | RATIONALE | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | RISK PATIENTS | PCSK9 | MONOCLONAL-ANTIBODY | EVOLOCUMAB | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypercholesterolemia - blood | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - therapeutic use | Intention to Treat Analysis | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Control | Monoclonal antibodies | Clinical trials | Cholesterol, LDL | Dosage and administration | Cardiovascular diseases | Risk factors | Statins | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Lipids | Cardiovascular disease | Cognition | Subtilisin | Injection | Myalgia | Angina | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Ischemia | Drug therapy | Heart diseases | Life Sciences | Human health and pathology | Food and Nutrition | Santé publique et épidémiologie
Journal Article
Circulation, ISSN 0009-7322, 08/2013, Volume 128, Issue 9, pp. 962 - 969
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 1532-6535, 2007, Volume 82, Issue 1, pp. 21 - 32
The low productivity and escalating costs of drug development have been well documented over the past several years. Less than 10... 
TRIPTANS SEROTONIN | METAANALYSIS | DOSE-RESPONSE | INTEGRATION | 5-HT1B/1D AGONISTS | PHARMACOLOGY & PHARMACY | SIMULATION | MIGRAINE | Analgesics - pharmacology | Muscarinic Agonists - pharmacology | Cholesterol - blood | Humans | Glycoproteins - pharmacology | Caproates - therapeutic use | Amines - therapeutic use | Alzheimer Disease - psychology | Neutrophil Infiltration - drug effects | United States Food and Drug Administration | Glycoproteins - therapeutic use | Alzheimer Disease - drug therapy | gamma-Aminobutyric Acid - pharmacology | Stroke - drug therapy | Cognition - drug effects | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Models, Biological | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Amines - pharmacology | Immunologic Factors - pharmacology | Clinical Trials as Topic - legislation & jurisprudence | Guidelines as Topic | Meta-Analysis as Topic | Clinical Trials as Topic - statistics & numerical data | United States | Caproates - pharmacology | Muscarinic Agonists - therapeutic use | Oximes - therapeutic use | Drug Approval | Hypercholesterolemia - drug therapy | Dose-Response Relationship, Drug | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Computer Simulation | Drug Design | gamma-Aminobutyric Acid - therapeutic use | Stroke - immunology | Analgesics - therapeutic use | Cyclohexanecarboxylic Acids - therapeutic use | Hypercholesterolemia - blood | Reproducibility of Results | Neuralgia, Postherpetic - drug therapy | Pharmacology | Models, Statistical | Animals | Anticholesteremic Agents - therapeutic use | Cyclohexanecarboxylic Acids - pharmacology | Oximes - pharmacology | Clinical Trials as Topic - methods | Pharmacokinetics | Research Design | Anticholesteremic Agents - pharmacology | Immunologic Factors - therapeutic use
Journal Article
Molecular therapy, ISSN 1525-0016, 2017, Volume 25, Issue 5, pp. 1069 - 1075
...Main Text The Earlier Food and Drug Administration Approvals Vitravene, Also Known as Fomivirsen The first antisense oligonucleotide approved for marketing... 
Kynamro | therapeutics | Spinraza | Defitelio | Vitravene | Macugen | aptamer | phosphorothioate | Eteplirsen | oligonucleotide | MEDICINE, RESEARCH & EXPERIMENTAL | FAMILIAL HYPERCHOLESTEROLEMIA | VENOOCCLUSIVE DISEASE | B SYNTHESIS INHIBITOR | APOLIPOPROTEIN-B | LDL CHOLESTEROL | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ENDOTHELIAL-CELLS | GENETICS & HEREDITY | DUCHENNE MUSCULAR-DYSTROPHY | EXTRACELLULAR-MATRIX | FIBROBLAST GROWTH-FACTORS | RECEPTOR-BINDING | Oligonucleotides - therapeutic use | Humans | Morpholinos - therapeutic use | Polydeoxyribonucleotides - therapeutic use | Drug Approval | Hepatic Veno-Occlusive Disease - therapy | Cytomegalovirus Retinitis - virology | Muscular Atrophy, Spinal - genetics | Hypercholesterolemia - pathology | Oligonucleotides, Antisense - therapeutic use | Hepatic Veno-Occlusive Disease - genetics | Hypercholesterolemia - therapy | Hepatic Veno-Occlusive Disease - pathology | Muscular Dystrophy, Duchenne - therapy | Cytomegalovirus Retinitis - therapy | Thionucleotides - therapeutic use | Aptamers, Nucleotide - therapeutic use | Muscular Dystrophy, Duchenne - pathology | Clinical Trials as Topic | Cytomegalovirus Retinitis - genetics | Muscular Atrophy, Spinal - pathology | Macular Degeneration - genetics | Macular Degeneration - therapy | Muscular Atrophy, Spinal - therapy | Hypercholesterolemia - genetics | Muscular Dystrophy, Duchenne - genetics | Macular Degeneration - pathology | Macular degeneration | Cytomegalovirus | Collaboration | Clinical trials | Antisense oligonucleotides | FDA approval | Mutation | Drug dosages | Binding sites | Marketing | Pharmaceuticals | Review
Journal Article